Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells

Clinical and Experimental Immunology

Volumn 146, Issue 1, 2006, Pages 181-188

  Luo, Y ^a   Yamada, H ^a   Evanoff, D P ^a   Chen, X ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

BCG; Bladder cancer; Cytokine; Cytotoxicity; Macrophage

Indexed keywords

BCG VACCINE; CARRIER PROTEIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; PROTEIN TH1; RECOMBINANT PROTEIN; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL CULTURE; CELL FUNCTION; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; IN VITRO STUDY; MACROPHAGE; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; BCG VACCINE; CELL DEATH; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C3H; RECOMBINANT PROTEINS; TH1 CELLS; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 33748691678     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03191.x     Document Type: Article

References (39)

1. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980; 124:38-40.
2. O'Donnell MA, DeWolf DC. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995; 4:189-202.
3. Emoto M, Emoto Y, Buchwalow IB, Kaufmann SH. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette-Guérin. Eur J Immunol 1999; 29:650-9.
4. Pryor K, Goddard J, Goldstein D et al. Bacillus Calmette-Guérin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 1995; 71:801-7.
5. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144:53-8.
6. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147:1636-42.
7. Peuchmaur M, Benoit G, Vieillefond A et al. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guérin. Urol Res 1989; 17:299-303.
8. Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA et al. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. Br J Urol 2001; 88:602-10.
9. De Boer EC, De Jong WH, Van Der Meijden AP et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 1991; 33:411-6.
10. De Boer EC, de Jong WH, van der Meijden AP et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 1991; 19:45-50.
11. De Boer EC, De Jong WH, Steerenberg PA et al. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guérin. In Vivo 1991; 5:671-7.
12. Bohle A, Nowc C, Ulmer AJ et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990; 144:59-64.
13. Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol 2000; 164:2129-33.
14. de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155:477-82.
15. Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. J Urol 2002; 167:364-7.
16. Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003; 21:17-26.
17. Wang J, Wakeham J, Harkness R, Xing Z. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J Clin Invest 1999; 103:1023-9.
18. Matsumoto H, Suzuki K, Tsuyuguchi K et al. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG. cytokine regulation and effect of NK cells. Infect Immun 1997; 65:4405-10.
19. Calorini L, Bianchini F, Mannini A et al. IFN-gamma and TNF-alpha account for a pro-clonogenic activity secreted by activated murine peritoneal macrophages. Clin Exp Metastasis 2002; 19:259-642.
20. Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM. Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber Lung Dis 2000; 80:197-207.
21. de Reijke TM, De Boer EC, Kurth KH, Schamhart DH. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guérin treatment. can it predict the optimal number of instillations? J Urol 1999; 161:67-71.
22. Hamerman JA, Aderem A. Functional transitions in macrophages during in vivo infection with Mycobacterium bovis bacillus Calmette-Guérin. J Immunol 2001; 167:2227-33.
23. Aldwell FE, Wedlock DN, Slobbe LJ, Griffin JF, Buddle BM, Buchan GS. In vitro control of Mycobacterium bovis by macrophages. Tuberculosis 2001; 81:115-23.
24. Luo Y, Yamada H, Chen X et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 2004; 137:24-34.
25. Yamada H, Kuroda E, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro. Clin Exp Immunol 2002; 128:52-8.
26. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Enhancing effect of an inhibitor of nitric oxide synthesis on bacillus Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro. Jpn J Cancer Res 2000; 91:534-42.
27. Mickey DD, Mickey GH, Murphy WM, Niell HB, Soloway MS. In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors. J Urol 1982; 127:1233-7.
28. O'Donnell MA, Aldovini A, Duda RB et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994; 62:2508-14.
29. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999; 17:593-623.
30. O'Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder. J Urol 2004; 171:1336-42.
31. Hawkyard SJ, Jackson AM, Prescott S, James K, Chisholm GD. The effect of recombinant cytokines on bladder cancer cells in vitro. J Urol 1993; 150:514-8.
32. Hawkyard S, James K, Prescott S et al. The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J Urol 1991; 145:1078-81.
33. Zhou A, Chen Z, Rummage JA et al. Exogenous interferon-gamma induces endogenous synthesis of interferon-alpha and -beta by murine macrophages for induction of nitric oxide synthase. J Interferon Cytokine Res 1995; 15:897-904.
34. Petricevich VL, Alves RC. Role of cytokines and nitric oxide in the induction of tuberculostatic macrophage functions. Med Inflamm 2000; 9:261-9.
35. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997; 65:4843-9.
36. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-40.
37. Ahn HJ, Maruo S, Tomura M et al. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol 1997; 159:2125-31.
38. Kohno K, Kataoka J, Ohtsuki T et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158:1541-50.
39. Luo Y, Chen X, Szilvasi A, O'Donnell MA. Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity. Mol Immunol 2000; 37:527-36.